Lilly’s Ramucirumab Disappoints With Small Overall Survival Advantage: Analysts

Drug Industry Daily
A A
Eli Lilly’s cancer drug ramucirumab achieved a statistically significant but small overall survival advantage in a key gastric cancer trial, underwhelming analysts Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily